ARK and Cathie Wood Reveal Passive >5% Stake in CRISPR Therapeutics

ARK Investment Management LLC and Cathie Wood, acting jointly under Rule 13d‑1(k)(1), submitted Amendment No. 13 to their original Schedule 13G filing. The amendment signals that the pair’s combined beneficial ownership of CRISPR Therapeutics’ common stock now surpasses the 5% threshold that triggers SEC reporting, but they remain classified as passive investors – meaning they do not intend to influence corporate governance.

The filing, signed by Kellen Carter, Chief Compliance Officer of ARK, and Wood herself as CEO and CIO, does not disclose the exact share count or percentage beyond the statutory “more than 5%” marker. Nonetheless, the move is noteworthy for a biotech whose shares have been on an upward trajectory, closing the most recent session at $52.62, up 3.78%—outpacing the S&P 500’s 0.92% gain.

CRISPR Therapeutics, a leader in CRISPR/Cas9‑based gene‑editing therapies, has been a magnet for investor interest, ranking among the most‑searched stocks on Zacks.com and drawing attention for its pipeline of transformative medicines. The firm’s market cap now sits at roughly $5.1 billion, with the stock positioned at the lower‑mid range of its 52‑week band (about 39%).

For shareholders, the ARK disclosure may be read as a vote of confidence from one of the sector’s most prominent active managers. While the filing does not imply any forthcoming activist agenda, the passive stake signals that ARK sees long‑term upside in CRISPR’s scientific platform and upcoming clinical milestones.

Analysts have noted that the biotech’s recent price performance—up 2.61% on the prior day and outperforming broader indices—combined with heightened search activity, suggests a growing market narrative around CRISPR’s potential. The ARK filing adds a layer of institutional validation to that narrative, reinforcing the stock’s appeal to both retail and professional investors.